Please login to the form below

SCLC

This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

in previously-untreated patients with extensive-stage SCLC, said to be the most aggressive for of lung cancer. ... SCLC is less common than non-small cell lung cancer (NSCLC) but tends to be more aggressive, growing more quickly and spreading to other

Latest news

Strike three for Rova-T has AbbVie cutting its losses

Approximately two-thirds of patients with SCLC have high levels of DLL3 on the surface of tumours, and the biomarker is thought to be absent from heathy adult tissues. ... MERU compared the ADC to placebo as maintenance therapy following first-line,
AZ’s Imfinzi joins immunotherapy drive in small cell lung cancer

Tecentriq the leader in setting. AstraZeneca’s Imfinzi is the latest PD-1/PD-L1 inhibitor to show clinical activity in small cell lung cancer (SCLC), extending survival when used as ... SCLC is a notoriously hard-to-treat disease that accounts for up
Merck says it has plenty in the pipe beyond Keytruda

cancer (SCLC), and with momentum only just starting to gather in renal cell carcinoma.
Keytruda begins pursuit of rivals in small cell lung cancer

as a third line therapy in SCLC, with Roche’s Tecentriq gaining a prized first line indication in March. ... This study focuses on recently-diagnosed patients with advanced-stage SCLC, which would put it in more direct competition with Tecentriq.
Encouraging early data for Amgen’s BiTE therapies

DLL3) in small-cell lung cancer (SCLC), with data presented on the candidates at ASCO poster sessions.

More from news
Approximately 3 fully matching, plus 21 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. .
Deal Watch April 2016

Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
Deal Watch November 2015

July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Account Manager – Healthcare advertising: Salary TBC

Events Executive: DOE

Senior Medical Writer: Competitive salary plus benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Client Services Director- Flexible Working: Negotiable

Account Director – UK Office: Excellent salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...